Anti-MUC1 Aptamer as Carrier Tool of the Potential Radiosensitizer 1,10 Phenanthroline in MCF-7 Breast Cancer Cells

Background: Proteins overexpressed in malignant tissues form important targets in the development of targeted therapeutics, and aptamers comprise an important affinity agent for therapy and drug delivery. In this study, aberrantly expressed mucin 1 glycoprotein was investigated as a therapeutic targ...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-04, Vol.39 (4), p.1859-1867
Main Authors: ALVES, LAÍS N., MISSAILIDIS, SOTIRIS, LAGE, CLAUDIA A. S., DE ALMEIDA, CARLOS EDUARDO B.
Format: Article
Language:English
Subjects:
Aptamers
Breast cancer
Circular dichroism
Cytotoxicity
Dichroism
Drug delivery
Drug delivery systems
Drug development
Feasibility studies
Flow cytometry
Fluorescence
Glycoproteins
Iron
Labeling
Microscopy
Mucin
Radiosensitizers
Rhodamine
Therapeutic applications
Therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Proteins overexpressed in malignant tissues form important targets in the development of targeted therapeutics, and aptamers comprise an important affinity agent for therapy and drug delivery. In this study, aberrantly expressed mucin 1 glycoprotein was investigated as a therapeutic target in a breast cancer model. Materials and Methods: In order to determine the feasibility of using an aptamer against mucin 1 (aptA) as carrier of the cytotoxic compound 1,10-phenanthroline to MCF-7 cells, as a potential radiosensitizer, was studied in experiments using circular dichroism and rhodamine labelling by fluorescent microscopy and flow cytometry. Results: 1,10-Phenanthroline can be intercalated within aptA when complexed with Fe(II) ions, with dissociation constant (Kd) of 30 μM. The complex was subsequently capable of binding to and being internalised in MCF-7 breast cancer cells. Conclusion: aptA can carry 1,10-phenanthroline to cancer cells specifically and this complex represents a potential target-directed anticancer therapy.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13293